enGene Holdings (ENGN) Stock Price, Quote, News & History

Comments

enGene Holdings Inc (ENGN) Stock Price, Quote, News & History

ENGNNASDAQ

Trade with Public

$6.37

-0.59-8.48%

At close: Mar 27, 5:00 PM EST

$6.90

0.538.32%

After Hours: Mar 24, 4:00 PM EST

OverviewNews Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$6.92

Close

$6.37

Volume / Avg.

162.39K / 423.84K

Day Range

$6.22 - $7.06

52 Wk Range

2.65 - 12.25

Market Cap

$462.23M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

28

Short Interest

1.77%

Days to Cover

1.02

Recent enGene Holdings Inc News

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.

Vandana Singh

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

Why enGene Holdings Stock Is Trading Higher

enGene shares are trading higher by 6.7% during Friday's session. The company announced it generated approximately $60 million in proceeds from a private placement.

Henry Khederian

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-102.45M

Investing Cash Flow (TTM)

-66.47M

Financing Cash Flow (TTM)

143.18M

Free Cash Flow (TTM)

-103.79M

Capital Expenditure (TTM)

-1.34M

Net Change in Cash (TTM)

-25.73M

Analyst Trends and Forecast

2

1

Nov 25

2

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$184.24M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.67

Earnings Yield % (TTM)

-32.03%

Earnings Yield % (FWD)

-29.96%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.20

Company Debt

Total Debt

$24.92M

LT Debt

$24.74M

LT Debt Issuance (TTM)

$25.00M

LT Debt Repayment (TTM)

-$23.75M

Total Cash

$36.61M

Debt to Equity

0.12

Issuance of Debt (TTM)

$1.25M

Repayment of Debt (TTM)

-$23.75M

Key Statistics

Open

$6.92

Close

$6.37

Volume / Avg.

162.39K / 423.84K

Day Range

$6.22 - $7.06

52 Wk Range

2.65 - 12.25

Market Cap

$462.23M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

28

Short Interest

1.77%

Days to Cover

1.02

About

Sector

Health Care

Industry

Biotechnology

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, be...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy enGene Holdings (ENGN) stock?

A

You can purchase shares of enGene Holdings (NASDAQ:ENGN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are enGene Holdings (ENGN) competitors?

A

Other companies in enGene Holdings’s space includes: 4D Molecular Therapeutics Inc (NASDAQ:FDMT), Larimar Therapeutics Inc (NASDAQ:LRMR), Altimmune Inc (NASDAQ:ALT), ADC Therapeutics SA (NYSE:ADCT) and Prothena Corp PLC (NASDAQ:PRTA).

Q

What is the forecast, or price target, for enGene Holdings (ENGN) stock?

A

enGene Holdings has a consensus price target of $24.33.

Q

What is the current price for enGene Holdings (ENGN)?

A

The stock price for enGene Holdings (NASDAQ: ENGN) is $6.9 last updated March 24, 2026 at 4:00 PM EDT.

Q

Does enGene Holdings (ENGN) pay a dividend?

A

There are no upcoming dividends for enGene Holdings.

Q

When is enGene Holdings (NASDAQ:ENGN) reporting earnings?

A

enGene Holdings does not have any upcoming earnings scheduled.

Q

Is enGene Holdings (ENGN) going to split?

A

There is no upcoming split for enGene Holdings.

Q

What sector and industry does enGene Holdings (ENGN) operate in?

A

enGene Holdings is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

4D Molecular Therapeutics Inc

NASDAQ:FDMT

$9.33

%

Larimar Therapeutics Inc

Eupraxia Pharmaceuticals Inc

NASDAQ:EPRX

$6.24

-7.14%

Kyverna Therapeutics Inc

NASDAQ:KYTX

$7.80

%

Ironwood Pharmaceuticals Inc

NASDAQ:IRWD

$3.08

0.59%

Key Statistics

Open

$6.92

Close

$6.37

Volume / Avg.

162.39K / 423.84K

Day Range

$6.22 - $7.06

52 Wk Range

2.65 - 12.25

Market Cap

$462.23M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

28

Short Interest

1.77%

Days to Cover

1.02

Recent enGene Holdings Inc News

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.

Vandana Singh

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

Why enGene Holdings Stock Is Trading Higher

enGene shares are trading higher by 6.7% during Friday's session. The company announced it generated approximately $60 million in proceeds from a private placement.

Henry Khederian

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-102.45M

Investing Cash Flow (TTM)

-66.47M

Financing Cash Flow (TTM)

143.18M

Free Cash Flow (TTM)

-103.79M

Capital Expenditure (TTM)

-1.34M

Net Change in Cash (TTM)

-25.73M

Analyst Trends and Forecast

2

1

Nov 25

2

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$184.24M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.67

Earnings Yield % (TTM)

-32.03%

Earnings Yield % (FWD)

-29.96%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.20

Company Debt

Total Debt

$24.92M

LT Debt

$24.74M

LT Debt Issuance (TTM)

$25.00M

LT Debt Repayment (TTM)

-$23.75M

Total Cash

$36.61M

Debt to Equity

0.12

Issuance of Debt (TTM)

$1.25M

Repayment of Debt (TTM)

-$23.75M

Key Statistics

Open

$6.92

Close

$6.37

Volume / Avg.

162.39K / 423.84K

Day Range

$6.22 - $7.06

52 Wk Range

2.65 - 12.25

Market Cap

$462.23M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

28

Short Interest

1.77%

Days to Cover

1.02

About

Sector

Health Care

Industry

Biotechnology

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, be...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry